GLG News by Council Members who Treat Colon/Colorectal Cancer
Articles with lock require a subscription to GLG News |
Request a free trial
October 28, 2008Vaccine for prostate cancer fails
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Recent Cell Genesys vaccine trial for prostate cancer fails
The trial not only shows lack of efficacy, but possible harm from the vaccine arm of the trial
October 27, 2008Hitting the target may reduce the use of targeted cancer drugs or not
Analysis of: Targeting EGFR in Colorectal Cancer | content.nejm.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
We are facing an ever increasing expense of treating cancver
The so called targeted drugs are the big price items
The recent discovery of theses drugs have sometimes been out of order with understanding their activity
October 24, 2008
A target may well decrease the market for EGFR inhibitors (Erbitux & Vectibix) in colon cancer (CRC)
Analysis of: Targeting EGFR in Colorectal Cancer | content.nejm.org
Author: GLG Expert Contributor
A target may well decrease the market for EGFR inhibitors (Erbitux & Vectibix) in colon cancer (CRC)Analysis of: Targeting EGFR in Colorectal Cancer | content.nejm.org
Author: GLG Expert Contributor
Measuring mutated K-RAS will show who will NOT respond to ImClone's Erbitux or Amgen's Vectibix. Thus to use either in CRC will not be particularly effective.
October 24, 2008The vaccine approach to cancer has yet to succeed
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Be cautious of vaccine approaches to cancer No cancer has had success with the use of vaccine therapy We are far from figuring out the reason for failure of vaccines to treat cancer
October 23, 2008
Vaccinate smokers?? what is the agenda and the employer of "The Advisory Committee on Immunization Practices."
Analysis of: Panel Calls for Vaccine for Adult Smokers | online.wsj.com
Author: GLG Expert Contributor
Vaccinate smokers?? what is the agenda and the employer of "The Advisory Committee on Immunization Practices."Analysis of: Panel Calls for Vaccine for Adult Smokers | online.wsj.com
Author: GLG Expert Contributor
31 million more doses of Pneumovax yearly in the US??
October 21, 2008
GVAX: Why did it fail? Let me list the possible ways......
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: GLG Expert Contributor
GVAX: Why did it fail? Let me list the possible ways......Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: GLG Expert Contributor
Cell Genesys is basically stopping work on GVAX inview of failure in two trials. The cause of the failure is not readily apparent.
October 20, 2008We must hit the cancer target by genetics or whatever technique
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Targeted therapy for cancer is the new trend
Targeted therapy will allow the use of more expensive drugs to be more practical
We need to focus on hitting a target more than ever
October 20, 2008Government Run Cancer care
Analysis of: Roche Cuts Price of Cancer Drug | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
There has been distubing trends in nationalized health care in regrds to cancer care
Recently the UK made an absolutely shocking decision on renal cancer therapy, as it has in other cancers in the past
Hopefully through advances in predicting cancer therapy outcomes via microarray etc. we can...
October 15, 2008
Thyroid cancer: When it rains it pours
Analysis of: Phase II Trial of Sorafenib in Advanced Thyroid Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
Thyroid cancer: When it rains it poursAnalysis of: Phase II Trial of Sorafenib in Advanced Thyroid Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
as per an accompanying editorial "In conclusion, it is particularly gratifying that years of research in tumor biology and drug development have coalesced. Translation of these research advances into therapeutic benefits for patients with refractory thyroid cancer, and a related paradigm shift...
October 15, 2008
Genetically determined cancer therapy: It will be a wash.
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Genetically determined cancer therapy: It will be a wash.Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Genetic determinants will decrease use of some drugs due to mutations such as Kras which indicate less chance of response and thus the chemo agents will not be used.
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 Next11 to 20 of 655
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Painkiller Risk Found for Heart Patients
www.nytimes.com
FDA Asks if Pain Pill Is Tamper-Proof
online.wsj.com
Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months
www.pipelinereview.com
Hospitals See Drop in Paying Patients
www.nytimes.com
Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
www.fiercebiotech.com
Is Celebrex Next ?
November 18, 2008
Will contact lens solutions cost more to ship and store?
November 13, 2008
Economy's impact on healthcare facilities
November 13, 2008
Tamper Proof Narcotic Pain pill? YES
November 13, 2008
A closer look
November 11, 2008